Table 1 Patients’ characteristics
N° (%) | |
|---|---|
976 | |
AGE, (years) | |
Median | 68 |
Range | 24–92 |
Elderly (≥ 70) | 445 (45.6) |
SEX | |
Male | 663 (67.9) |
Female | 313 (32.1) |
ECOG PS | |
0–1 | 831 (85.1) |
≥ 2 | 145 (14.9) |
Primary Tumor | |
NSCLC | 635 (65.1) |
Melanoma | 183 (18.7) |
Renal cell carcinoma | 135 (13.8) |
Others | 23 (2.4) |
No. of metastatic sites | |
≤ 2 | 467 (47.9) |
> 2 | 509 (52.1) |
Type of anti-PD-1/PD-L1 agent | |
Pembrolizumab | 235 (24.1) |
Nivolumab | 706 (72.3) |
Atezolizumab | 35 (3.6) |
Treatment line of Immunotherapy | |
First | 260 (26.6) |
Non-First | 716 (73.4) |
Weight (Kg) | |
Median | 71 |
Range | 35–139 |
BMI (kg/m2) | |
Median (range) | 24.9 (13.5–46.6) |
Underweight (BMI ≤ 18.5), n°(%) | 40 (4.1) |
Normal weight (BMI 18.5 < BMI ≤ 24.9), n°(%) | 452 (46.3) |
Overweight (25 < BMI ≤ 29.9), n°(%) | 377 (38.6) |
Obese (BMI ≥ 30), n° (%) | 107 (11) |